BridgeMD
New treatment option for Intracranial Atherosclerosis
Official title Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis
ClinicalTrials.gov ID: NCT07282041
What this study is testing
What is Dulaglutide?
Dulaglutide is an investigational medicine, given as an once-weekly injection under the skin, being studied as a potential treatment for intracranial atherosclerosis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- One important mechanism of action of GLP1 RA is the improvement in endothelial function, which may be evaluated by the assessment of cerebral vasodilatory reserve (CVR) in patients with severe ICAD. The investigators believe that GLP1 RA would be beneficial for patients with severe ICAD and lead to an improvement in cerebral vasodilatory reserve (CVR) in patients with severe and recently symptomatic stenosis of intracranial carotid artery (ICA) or middle cerebral artery (MCA).
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 21 to 80
You may be able to join if
- Adult patients aged 21 - 80 years old inclusive,
- Able to provide consent,
- Score 3 or less on the Modified Rankin Score (mRS),
- Patients with TIA or mild stroke with severe stenosis of intracranial ICA or MCA and impaired CVR within previous 3-months of acute stroke or TIA
You likely can't join if
- Chronic kidney disease stage 5 (eGFR\<15 mL/min) or on dialysis,
- Cancer diagnosed within past 3 years,
- Currently being planned for coronary or carotid artery revascularization,
- History of previous pancreatitis,
- History of medullary thyroid cancer,
- Atrial fibrillation,
See the full eligibility criteria
- Adult patients aged 21 - 80 years old inclusive,
- Able to provide consent,
- Score 3 or less on the Modified Rankin Score (mRS),
- Patients with TIA or mild stroke with severe stenosis of intracranial ICA or MCA and impaired CVR within previous 3-months of acute stroke or TIA
- Chronic kidney disease stage 5 (eGFR\<15 mL/min) or on dialysis,
- Cancer diagnosed within past 3 years,
- Currently being planned for coronary or carotid artery revascularization,
- History of previous pancreatitis,
- History of medullary thyroid cancer,
- Atrial fibrillation,
- Any other condition likely to limit protocol compliance (judged by investigator).
- For diabetic patients, patients should not be on Sodium-glucose cotransporter 2 (SGLT2) inhibitor or pioglitazone during the duration of the study, unless these drugs can be stopped without affecting participants'...
- Known allergies to Acetazolamide.
- Women who are pregnant or breastfeeding.
The study team makes the final eligibility decision.
Where it's taking place
- Singapore, Singapore
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 21 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Singapore, Singapore. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.